文献速递白血病

初诊晚期慢性髓性白血病预后主要由原始细胞计数决定,也受年龄、染色体异常和血红蛋白影响

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
PubMed 文献 · Am J Hematol · 2019-09-14

研究基于EUTOS登记中283例初诊晚期慢性髓性白血病患者,绝大多数接受酪氨酸激酶抑制剂治疗,中位生存8.2年。

要点

  • 原始细胞计数是初诊晚期CML最重要的预后因素。

核心结论

  • 初诊晚期CML预后主要由原始细胞计数决定,年龄、血红蛋白、嗜碱性粒细胞和其他染色体异常也应考虑。
  • 数据支持20%而非30%作为原始细胞危象切点,建议对初诊晚期CML采用单期而非两期分类。

研究设计与样本

  • 从EUTOS人群登记和out-study登记中识别283例初诊晚期CML患者。
  • 绝大多数患者接受酪氨酸激酶抑制剂治疗。

主要发现

  • 该异质性队列中位生存8.2年。
  • >30%原始细胞者与20-29%者比较,HR 1.32(95%CI 0.7-2.6)。

关键数值与推荐

  • 原始细胞>30% vs 20-29%:HR 1.32(95%CI 0.7-2.6)。

临床怎么用

  • 对初诊晚期CML应重视原始细胞计数,并综合年龄、血红蛋白、嗜碱性粒细胞和染色体异常评估预后。
  • 可采用ELTS评分区分高风险与非高风险患者。
  • 原始细胞危象定义宜采用20%切点,并对初诊晚期CML采用单期分类。

局限性

  • 晚期CML患者比例小,队列异质性大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML) is usually diagnosed in chronic phase, yet there is a small percentage of patients that is diagnosed in accelerated phase or blast crisis. Due to this rarity, little is known about the prognosis of these patients. Our aim was to identify prognostic factors for this cohort. We identified 283 patients in the EUTOS population-based and out-study registries that were diagnosed in advanced phase. Nearly all patients were treated with tyrosine kinase inhibitors. Median survival in this heterogeneous cohort was 8.2 years. When comparing patients with more than 30% blasts to those with 20-29% blasts, the hazard ratio (HR) was 1.32 (95%-confidence interval (CI): [0.7-2.6]). Patients with 20-29% blasts had a significantly higher risk than patients with less than 20% blasts (HR: 2.24, 95%-CI: [1.2-4.0], P = .008). We found that the blast count was the most important prognostic factor; however, age, hemoglobin, basophils and other chromosomal aberrations should be considered as well. The ELTS score was able to define two groups (high risk vs non-high risk) with an HR of 3.01 (95%-CI: [1.81-5.00], P < .001). Regarding the contrasting definitions of blast crisis, our data clearly supported the 20% cut-off over the 30% cut-off in this cohort. Based on our results, we conclude that a one-phase rather than a two-phase categorization of de novo advanced phase CML patients is appropriate.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lauseker M, Bachl K, Turkina A, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019. PMID: 31456269. doi:10.1002/ajh.25628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。